← Back 
TYRA
Tyra Biosciences · Biotech · ~$1.4B
$36.52 -0.63
(-1.70%)
BUY 72
Live quote as of
Hold Period
Medium-Term (Event-Driven)
Hot Streak
— None
Position Size
4%
Earnings
Jun 5 (74d)
Sector RS
In-Line
Why We Like It
Precision oncology. Dabogratinib for bladder cancer.
Investment Strategy
Medium-Term (Event-Driven)
Position small pre-catalyst. Trim half on data readout pop.
Recommended allocation: 4% — Small / speculative
Confidence Breakdown
Fundamentals (35%) 68
Technicals (25%) 72
Sentiment (20%) 70
Catalysts (15%) 78
Risk Adjusted (5%) 68
Overall Score 72
Bull Case
First-in-class potential. 9/9 Strong Buy. Target $43.50.
Bear Case
Pre-revenue biotech. Binary FDA risk.
Analyst Consensus
18 analysts covering this stock · Period: 2026-03-01
8
9
Strong Buy: 8 Buy: 9 Hold: 1 Sell: 0 Strong Sell: 0
About Tyra Biosciences Inc
Log in to continue
Create a free account to access the full RichSense intelligence dashboard.
Log In Don't have an account? Subscribe free